banter and General Discussion, page-6752

It's the hype, my man.

It popped (and retraced) on the nothing news that they didn't fail inspection, which was also packaged into the financial report showing increased spending and still only 4% growth in revenue - thats hype. Price surging on the slightest hint of good news, even if it's still overall bad.

Of course if it gets fda approval it will pop. But will that price be due to the fundamentals, or still hype?

As I explained, the fundamentals are still not very strong even with approval - there's many companies with approval that still don't do well, due to extreme costs, difficulty with market penetration, etc.

What is the value of a hugely loss producing company that grows its revenue at only 4% per year 3 years after market entry?

$50b? like some here are predicting?

I'm just being realistic. And because it goes against the hype, it's seen as negative. I hope the product works, from a medical perspective that would be great. Just not convinced.

And the last thing we need is a wildly expensive product that doesn't work draining the bank accounts of families in need, promising hope but not delivering.

That's not to say it doesn't work. But that's the argument on the other side of the table.